↓ Skip to main content

Cochrane Database of Systematic Reviews

Antiplatelet agents for chronic kidney disease

Overview of attention for article published in this source, February 2013
Altmetric Badge


78 Dimensions

Readers on

41 Mendeley
1 CiteULike
Antiplatelet agents for chronic kidney disease
Published by
John Wiley & Sons, Ltd, February 2013
DOI 10.1002/14651858.cd008834.pub2
Pubmed ID

Palmer, Suetonia C, Di Micco, Lucia, Razavian, Mona, Craig, Jonathan C, Perkovic, Vlado, Pellegrini, Fabio, Jardine, Meg J, Webster, Angela C, Zoungas, Sophia, Strippoli, Giovanni FM


Antiplatelet agents are widely used to prevent cardiovascular events. The risks and benefits of antiplatelet treatment may be different in people with chronic kidney disease (CKD) for whom occlusive atherosclerotic events are less prevalent, and bleeding hazards might be increased.

Twitter Demographics

The data shown below were collected from the profiles of 9 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 41 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
India 1 2%
Russia 1 2%
France 1 2%
Unknown 38 93%

Demographic breakdown

Readers by professional status Count As %
Researcher 5 12%
Other 5 12%
Student > Postgraduate 3 7%
Student > Bachelor 3 7%
Student > Master 3 7%
Other 8 20%
Unknown 14 34%
Readers by discipline Count As %
Medicine and Dentistry 19 46%
Agricultural and Biological Sciences 2 5%
Biochemistry, Genetics and Molecular Biology 1 2%
Psychology 1 2%
Pharmacology, Toxicology and Pharmaceutical Science 1 2%
Other 0 0%
Unknown 17 41%